$0.55 EPS Expected for Banco Latinoamericano de Comercio Exterior, S.A (BLX); Regenxbio (RGNX) Shorts Lowered By 6.18%

February 15, 2018 - By Louis Casey

Analysts expect Banco Latinoamericano de Comercio Exterior, S.A (NYSE:BLX) to report $0.55 EPS on February, 16.They anticipate $0.21 EPS change or 61.76% from last quarter’s $0.34 EPS. BLX’s profit would be $21.65 million giving it 12.98 P/E if the $0.55 EPS is correct. After having $0.52 EPS previously, Banco Latinoamericano de Comercio Exterior, S.A’s analysts see 5.77% EPS growth. The stock increased 1.35% or $0.38 during the last trading session, reaching $28.55. About 90,130 shares traded. Banco Latinoamericano de Comercio Exterior, S.A (NYSE:BLX) has risen 6.36% since February 15, 2017 and is uptrending. It has underperformed by 10.34% the S&P500.

Regenxbio Incorporated (NASDAQ:RGNX) had a decrease of 6.18% in short interest. RGNX’s SI was 1.24 million shares in February as released by FINRA. Its down 6.18% from 1.32 million shares previously. With 237,200 avg volume, 5 days are for Regenxbio Incorporated (NASDAQ:RGNX)’s short sellers to cover RGNX’s short positions. The SI to Regenxbio Incorporated’s float is 5.14%. The stock increased 0.75% or $0.2 during the last trading session, reaching $26.8. About 268,298 shares traded. Regenxbio Inc. (NASDAQ:RGNX) has risen 51.43% since February 15, 2017 and is uptrending. It has outperformed by 34.73% the S&P500.

Banco Latinoamericano de Comercio Exterior, S.A., a multinational bank, primarily engages in the financing of foreign trade in Latin America and the Caribbean. The company has market cap of $1.12 billion. It operates in two divisions, Commercial and Treasury. It has a 15.02 P/E ratio. The firm offers short and medium-term bilateral, collateral-backed, short and medium term trade, and pre-export financing structured loans; and discounting of notes, cross-border leasing, pre- and post-export financing, import financing, letters of credit, bank guarantees, documentary collection, irrevocable reimbursement undertakings, bankers' acceptance, vendor finance, and ECA-backed financing services.

REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins that are intended to impact disease. The company has market cap of $834.69 million. The Company’s gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. It currently has negative earnings. The companyÂ’s lead product candidate is RGX-314 for the treatment of wet age-related macular degeneration.

Among 4 analysts covering Regenxbio (NASDAQ:RGNX), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Regenxbio has $33 highest and $29 lowest target. $31’s average target is 15.67% above currents $26.8 stock price. Regenxbio had 4 analyst reports since October 12, 2015 according to SRatingsIntel. The stock of Regenxbio Inc. (NASDAQ:RGNX) has “Buy” rating given on Tuesday, October 20 by Chardan Capital Markets. The rating was initiated by Morgan Stanley on Tuesday, October 13 with “Overweight”. The stock of Regenxbio Inc. (NASDAQ:RGNX) earned “Overweight” rating by Piper Jaffray on Monday, October 12. As per Monday, October 12, the company rating was initiated by Bank of America.

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>